메뉴 건너뛰기




Volumn 7, Issue 1, 2014, Pages

New antibody approaches to lymphoma therapy

Author keywords

Antibodies; Bispecific T cell engager; Cd 20; Cd 22; Lymphoma; Monoclonal; Pd 1

Indexed keywords

ALEMTUZUMAB; BLINATUMOMAB; CD19 ANTIGEN; CD22 ANTIGEN; CD40 ANTIGEN; CD52 ANTIGEN; CHEMOKINE RECEPTOR CCR4; DACETUZUMAB; EPRATUZUMAB; LUCATUMUMAB; MEDI 551; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCARATUZUMAB; OCRELIZUMAB; OFATUMUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR ANTIGEN;

EID: 84908213051     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0058-4     Document Type: Review
Times cited : (50)

References (124)
  • 2
    • 49349095724 scopus 로고    scopus 로고
    • Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
    • Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626.
    • (2008) N Engl J Med , vol.359 , pp. 613-626
    • Cheson, B.D.1    Leonard, J.P.2
  • 3
    • 79955806814 scopus 로고    scopus 로고
    • Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results
    • Brody J, Kohrt H, Marabelle A, Levy R: Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results. J Clin Oncol 2011, 29:1864-1875.
    • (2011) J Clin Oncol , vol.29 , pp. 1864-1875
    • Brody, J.1    Kohrt, H.2    Marabelle, A.3    Levy, R.4
  • 4
    • 84879384673 scopus 로고    scopus 로고
    • Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
    • Brentjens RJ, Curran KJ: Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program 2012, 2012:143-151.
    • (2012) Hematology Am Soc Hematol Educ Program , vol.2012 , pp. 143-151
    • Brentjens, R.J.1    Curran, K.J.2
  • 6
    • 84864504946 scopus 로고    scopus 로고
    • Radioimmunotherapy for B-cell non-hodgkin lymphomas
    • Tomblyn M: Radioimmunotherapy for B-cell non-hodgkin lymphomas. Cancer Control 2012, 19:196-203.
    • (2012) Cancer Control , vol.19 , pp. 196-203
    • Tomblyn, M.1
  • 7
    • 84877575144 scopus 로고    scopus 로고
    • Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    • Kochenderfer JN, Rosenberg SA: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013, 10:267-276.
    • (2013) Nat Rev Clin Oncol , vol.10 , pp. 267-276
    • Kochenderfer, J.N.1    Rosenberg, S.A.2
  • 9
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    • Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99: 754-758.
    • (2002) Blood , vol.99 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3    Solal-Celigny, P.4    Bardos, P.5    Colombat, P.6    Watier, H.7
  • 10
    • 27144497346 scopus 로고    scopus 로고
    • Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)
    • Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16: 1675-1682.
    • (2005) Ann Oncol , vol.16 , pp. 1675-1682
    • Ghielmini, M.1    Rufibach, K.2    Salles, G.3    Leoncini-Franscini, L.4    Leger-Falandry, C.5    Cogliatti, S.6    Fey, M.7    Martinelli, G.8    Stahel, R.9    Lohri, A.10    Ketterer, N.11    Wernli, M.12    Cerny, T.13    Schmitz, S.F.14
  • 11
    • 0642373290 scopus 로고    scopus 로고
    • Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
    • Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J ClinOncol 2003, 21: 3940-3947.
    • (2003) J ClinOncol , vol.21 , pp. 3940-3947
    • Weng, W.K.1    Levy, R.2
  • 13
    • 0141704595 scopus 로고    scopus 로고
    • CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts
    • Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS: CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003, 63:5480-5489.
    • (2003) Cancer Res , vol.63 , pp. 5480-5489
    • Chan, H.T.1    Hughes, D.2    French, R.R.3    Tutt, A.L.4    Walshe, C.A.5    Teeling, J.L.6    Glennie, M.J.7    Cragg, M.S.8
  • 14
    • 1642306050 scopus 로고    scopus 로고
    • Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
    • Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
    • (2004) Blood , vol.103 , pp. 2738-2743
    • Cragg, M.S.1    Glennie, M.J.2
  • 15
    • 34548221347 scopus 로고    scopus 로고
    • Mechanisms of killing by anti-CD20 monoclonal antibodies
    • Glennie MJ, French RR, Cragg MS, Taylor RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
    • (2007) Mol Immunol , vol.44 , pp. 3823-3837
    • Glennie, M.J.1    French, R.R.2    Cragg, M.S.3    Taylor, R.P.4
  • 16
    • 84892422452 scopus 로고    scopus 로고
    • Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
    • Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M: Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013, 122:3482-3491.
    • (2013) Blood , vol.122 , pp. 3482-3491
    • Golay, J.1    Da Roit, F.2    Bologna, L.3    Ferrara, C.4    Leusen, J.H.5    Rambaldi, A.6    Klein, C.7    Introna, M.8
  • 18
    • 7244248664 scopus 로고    scopus 로고
    • From the bench to the bedside: Ways to improve rituximab efficacy
    • Cartron G, Watier H, Golay J, Solal-Celigny P: From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635-2642.
    • (2004) Blood , vol.104 , pp. 2635-2642
    • Cartron, G.1    Watier, H.2    Golay, J.3    Solal-Celigny, P.4
  • 19
    • 38949121647 scopus 로고    scopus 로고
    • NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
    • Wang SY, Racila E, Taylor RP, Weiner GJ: NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008, 111:1456-1463.
    • (2008) Blood , vol.111 , pp. 1456-1463
    • Wang, S.Y.1    Racila, E.2    Taylor, R.P.3    Weiner, G.J.4
  • 25
    • 84874835426 scopus 로고    scopus 로고
    • Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties
    • Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC: Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013, 190:2702-2711.
    • (2013) J Immunol , vol.190 , pp. 2702-2711
    • Rafiq, S.1    Butchar, J.P.2    Cheney, C.3    Mo, X.4    Trotta, R.5    Caligiuri, M.6    Jarjoura, D.7    Tridandapani, S.8    Muthusamy, N.9    Byrd, J.C.10
  • 27
    • 81055148076 scopus 로고    scopus 로고
    • Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study
    • Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011, 118:5126-5129.
    • (2011) Blood , vol.118 , pp. 5126-5129
    • Wierda, W.G.1    Padmanabhan, S.2    Chan, G.W.3    Gupta, I.V.4    Lisby, S.5    Osterborg, A.6
  • 42
    • 84899425454 scopus 로고    scopus 로고
    • Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others
    • Kobayashi H, Matsunaga Y, Uchiyama Y, Nagura K, Komatsu Y: Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others. Cancer Med 2013, 2:130-143.
    • (2013) Cancer Med , vol.2 , pp. 130-143
    • Kobayashi, H.1    Matsunaga, Y.2    Uchiyama, Y.3    Nagura, K.4    Komatsu, Y.5
  • 46
    • 80054118081 scopus 로고    scopus 로고
    • Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox
    • Kreitman RJ, Pastan I: Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011, 17:6398-6405.
    • (2011) Clin Cancer Res , vol.17 , pp. 6398-6405
    • Kreitman, R.J.1    Pastan, I.2
  • 47
    • 0030993376 scopus 로고    scopus 로고
    • CD22, A B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling
    • Tedder TF, Tuscano J, Sato S, Kehrl JH: CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997, 15:481-504.
    • (1997) Annu Rev Immunol , vol.15 , pp. 481-504
    • Tedder, T.F.1    Tuscano, J.2    Sato, S.3    Kehrl, J.H.4
  • 48
    • 0029025026 scopus 로고
    • Constitutive endocytosis and degradation of CD22 by human B cells
    • Shan D, Press OW: Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 1995, 154:4466-4475.
    • (1995) J Immunol , vol.154 , pp. 4466-4475
    • Shan, D.1    Press, O.W.2
  • 49
    • 0028349727 scopus 로고
    • Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2
    • Shih LB, Lu HH, Xuan H, Goldenberg DM: Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994, 56:538-545.
    • (1994) Int J Cancer , vol.56 , pp. 538-545
    • Shih, L.B.1    Lu, H.H.2    Xuan, H.3    Goldenberg, D.M.4
  • 54
    • 55849128896 scopus 로고    scopus 로고
    • Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma
    • Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM: Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008, 113:2714-2723.
    • (2008) Cancer , vol.113 , pp. 2714-2723
    • Leonard, J.P.1    Schuster, S.J.2    Emmanouilides, C.3    Couture, F.4    Teoh, N.5    Wegener, W.A.6    Coleman, M.7    Goldenberg, D.M.8
  • 56
    • 0037396183 scopus 로고    scopus 로고
    • CD22 as a target of passive immunotherapy
    • Cesano A, Gayko U: CD22 as a target of passive immunotherapy. Semin Oncol 2003, 30:253-257.
    • (2003) Semin Oncol , vol.30 , pp. 253-257
    • Cesano, A.1    Gayko, U.2
  • 57
    • 39649097409 scopus 로고    scopus 로고
    • Germinal center structure and function: Lessons from CD19
    • Carter RH, Myers R: Germinal center structure and function: lessons from CD19. Semin Immunol 2008, 20:43-48.
    • (2008) Semin Immunol , vol.20 , pp. 43-48
    • Carter, R.H.1    Myers, R.2
  • 58
    • 70349973753 scopus 로고    scopus 로고
    • CD19: A promising B cell target for rheumatoid arthritis
    • Tedder TF: CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5: 572-577.
    • (2009) Nat Rev Rheumatol , vol.5 , pp. 572-577
    • Tedder, T.F.1
  • 59
    • 0030901968 scopus 로고    scopus 로고
    • The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity
    • Tedder TF, Inaoki M, Sato S: The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997, 6:107-118.
    • (1997) Immunity , vol.6 , pp. 107-118
    • Tedder, T.F.1    Inaoki, M.2    Sato, S.3
  • 63
    • 0029075329 scopus 로고
    • Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas
    • Gruss HJ, Dower SK: Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995, 85:3378-3404.
    • (1995) Blood , vol.85 , pp. 3378-3404
    • Gruss, H.J.1    Dower, S.K.2
  • 65
    • 0025630628 scopus 로고
    • Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells
    • Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA: Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990, 76:2449-2456.
    • (1990) Blood , vol.76 , pp. 2449-2456
    • Uckun, F.M.1    Gajl-Peczalska, K.2    Myers, D.E.3    Jaszcz, W.4    Haissig, S.5    Ledbetter, J.A.6
  • 66
    • 84856098280 scopus 로고    scopus 로고
    • The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
    • Aldinucci D, Gloghini A, Pinto A, Colombatti A, Carbone A: The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma 2012, 53:195-201.
    • (2012) Leuk Lymphoma , vol.53 , pp. 195-201
    • Aldinucci, D.1    Gloghini, A.2    Pinto, A.3    Colombatti, A.4    Carbone, A.5
  • 67
    • 77956324601 scopus 로고    scopus 로고
    • CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
    • Rydstrom K, Linderoth J, Nyman H, Ehinger M, Joost P, Bendahl PO, Leppa S, Jerkeman M: CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2010, 51:1643-1648.
    • (2010) Leuk Lymphoma , vol.51 , pp. 1643-1648
    • Rydstrom, K.1    Linderoth, J.2    Nyman, H.3    Ehinger, M.4    Joost, P.5    Bendahl, P.O.6    Leppa, S.7    Jerkeman, M.8
  • 72
    • 79960432161 scopus 로고    scopus 로고
    • Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma
    • Lewis TS, McCormick RS, Emmerton K, Lau JT, Yu SF, McEarchern JA, Grewal IS, Law CL: Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res 2011, 17:4672-4681.
    • (2011) Clin Cancer Res , vol.17 , pp. 4672-4681
    • Lewis, T.S.1    McCormick, R.S.2    Emmerton, K.3    Lau, J.T.4    Yu, S.F.5    McEarchern, J.A.6    Grewal, I.S.7    Law, C.L.8
  • 74
    • 76349120845 scopus 로고    scopus 로고
    • A phase I study of dacetuzumab (SGN-40, A humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
    • Furman RR, Forero-Torres A, Shustov A, Drachman JG: A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010, 51:228-235.
    • (2010) Leuk Lymphoma , vol.51 , pp. 228-235
    • Furman, R.R.1    Forero-Torres, A.2    Shustov, A.3    Drachman, J.G.4
  • 77
    • 0034775122 scopus 로고    scopus 로고
    • Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
    • Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A: Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001, 2:300-306.
    • (2001) Hematol J , vol.2 , pp. 300-306
    • Rossmann, E.D.1    Lundin, J.2    Lenkei, R.3    Mellstedt, H.4    Osterborg, A.5
  • 80
    • 0027283918 scopus 로고
    • Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen
    • Xia MQ, Hale G, Waldmann H: Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993, 30:1089-1096.
    • (1993) Mol Immunol , vol.30 , pp. 1089-1096
    • Xia, M.Q.1    Hale, G.2    Waldmann, H.3
  • 81
    • 40349114506 scopus 로고    scopus 로고
    • FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia
    • Demko S, Summers J, Keegan P, Pazdur R: FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008, 13:167-174.
    • (2008) Oncologist , vol.13 , pp. 167-174
    • Demko, S.1    Summers, J.2    Keegan, P.3    Pazdur, R.4
  • 84
    • 1842579580 scopus 로고    scopus 로고
    • A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    • Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
    • (2004) Blood , vol.103 , pp. 2920-2924
    • Enblad, G.1    Hagberg, H.2    Erlanson, M.3    Lundin, J.4    MacDonald, A.P.5    Repp, R.6    Schetelig, J.7    Seipelt, G.8    Osterborg, A.9
  • 90
    • 33748933230 scopus 로고    scopus 로고
    • CCR4 as a novel molecular target for immunotherapy of cancer
    • Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006, 97:1139-1146.
    • (2006) Cancer Sci , vol.97 , pp. 1139-1146
    • Ishida, T.1    Ueda, R.2
  • 93
    • 84908210431 scopus 로고    scopus 로고
    • CO26. Results of a phase 1/2 study for KW-0761, A monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients
    • Kim Y, Pinter-Brown L, Foss F, Sokol L, Jorgensen J, Spitalny G, Duvic M: CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Melanoma Res 2011, 21:e15-e16.
    • (2011) Melanoma Res , vol.21 , pp. e15-e16
    • Kim, Y.1    Pinter-Brown, L.2    Foss, F.3    Sokol, L.4    Jorgensen, J.5    Spitalny, G.6    Duvic, M.7
  • 96
    • 34547655923 scopus 로고    scopus 로고
    • A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment
    • Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL: A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007, 13:4345-4354.
    • (2007) Clin Cancer Res , vol.13 , pp. 4345-4354
    • Strauss, L.1    Bergmann, C.2    Szczepanski, M.3    Gooding, W.4    Johnson, J.T.5    Whiteside, T.L.6
  • 97
    • 42149152160 scopus 로고    scopus 로고
    • CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
    • Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008, 122:2286-2293.
    • (2008) Int J Cancer , vol.122 , pp. 2286-2293
    • Mizukami, Y.1    Kono, K.2    Kawaguchi, Y.3    Akaike, H.4    Kamimura, K.5    Sugai, H.6    Fujii, H.7
  • 98
    • 62449250053 scopus 로고    scopus 로고
    • Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome
    • Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69:2000-2009.
    • (2009) Cancer Res , vol.69 , pp. 2000-2009
    • Gobert, M.1    Treilleux, I.2    Bendriss-Vermare, N.3    Bachelot, T.4    Goddard-Leon, S.5    Arfi, V.6    Biota, C.7    Doffin, A.C.8    Durand, I.9    Olive, D.10
  • 101
    • 84864324543 scopus 로고    scopus 로고
    • Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
    • Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T: Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012, 209:1201-1217.
    • (2012) J Exp Med , vol.209 , pp. 1201-1217
    • Yokosuka, T.1    Takamatsu, M.2    Kobayashi-Imanishi, W.3    Hashimoto-Tane, A.4    Azuma, M.5    Saito, T.6
  • 107
    • 79960318715 scopus 로고    scopus 로고
    • Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells
    • Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM: Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 2011, 17:4232-4244.
    • (2011) Clin Cancer Res , vol.17 , pp. 4232-4244
    • Andorsky, D.J.1    Yamada, R.E.2    Said, J.3    Pinkus, G.S.4    Betting, D.J.5    Timmerman, J.M.6
  • 108
    • 84887316694 scopus 로고    scopus 로고
    • Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
    • Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH: Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013, 27:2251-2253.
    • (2013) Leukemia , vol.27 , pp. 2251-2253
    • Munir, S.1    Andersen, G.H.2    Woetmann, A.3    Odum, N.4    Becker, J.C.5    Andersen, M.H.6
  • 109
    • 84908182014 scopus 로고    scopus 로고
    • Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers
    • Prochazka V, Novak M, Pikalova Z, Papajik T, Indrak K, Divoky V: Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers. ASH Annu Meet Abstr 2012, 120:2670.
    • (2012) ASH Annu Meet Abstr , vol.120 , pp. 2670
    • Prochazka, V.1    Novak, M.2    Pikalova, Z.3    Papajik, T.4    Indrak, K.5    Divoky, V.6
  • 110
    • 49649114804 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetic study of CT-011, A humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    • Berger R, Rotem-Yehudar R, Slama G: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
    • (2008) Clin Cancer Res , vol.14 , pp. 3044-3051
    • Berger, R.1    Rotem-Yehudar, R.2    Slama, G.3
  • 116
    • 84901602398 scopus 로고    scopus 로고
    • Nivolumab: Promising survival signal coupled with limited toxicity raises expectations
    • O'Sullivan Coyne G, Madan RA, Gulley JL: Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol 2014, 32:986-988.
    • (2014) J Clin Oncol , vol.32 , pp. 986-988
    • O'Sullivan Coyne, G.1    Madan, R.A.2    Gulley, J.L.3
  • 117
    • 67449156132 scopus 로고    scopus 로고
    • Bispecific T-cell engaging antibodies for cancer therapy
    • Baeuerle PA, Reinhardt C: Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009, 69:4941-4944.
    • (2009) Cancer Res , vol.69 , pp. 4941-4944
    • Baeuerle, P.A.1    Reinhardt, C.2
  • 120
    • 84908157861 scopus 로고    scopus 로고
    • Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    • Goebeler M, Pfreundschuh M, Adrian N, Libicher M, Degenhard E, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC: Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood 2013, 122:1811.
    • (2013) Blood , vol.122 , pp. 1811
    • Goebeler, M.1    Pfreundschuh, M.2    Adrian, N.3    Libicher, M.4    Degenhard, E.5    Stieglmaier, J.6    Zhang, A.7    Nagorsen, D.8    Bargou, R.C.9
  • 124
    • 84908156497 scopus 로고    scopus 로고
    • AACR Cancer Report 2013 - Special Feature on Immunotherapy
    • Pardoll D: AACR Cancer Report 2013 - Special Feature on Immunotherapy. Clin Cancer Res 2013, 19(Supplement 1):S1-S88.
    • (2013) Clin Cancer Res , vol.19 , pp. S1-S88
    • Pardoll, D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.